D Fintini1, S Pedicelli2, S Bocchini3, C Bizzarri2, G Grugni4, M Cappa2, A Crinò5. 1. Endocrinology Unit, Pediatric University Department, Bambino Gesù Children's Hospital, Research Institute, L.Go S.Onofrio, 4-00168, Rome, Italy. danilo.fintini@opbg.net. 2. Endocrinology Unit, Pediatric University Department, Bambino Gesù Children's Hospital, Research Institute, L.Go S.Onofrio, 4-00168, Rome, Italy. 3. Autoimmune Endocrine Diseases Unit, Bambino Gesù Children's Hospital, Research Institute, L.Go S.Onofrio, 4-00168, Rome, Italy. 4. Italian Auxological Institute, Piancavallo, Verbania, Italy. 5. Autoimmune Endocrine Diseases Unit, Bambino Gesù Children's Hospital, Research Institute, L.Go S.Onofrio, 4-00168, Rome, Italy. antonino.crino@opbg.net.
Abstract
PURPOSE: Obesity, insulin resistance, and puberty seem to influence and been inversely associated with 25-hydroxy vitamin D (25OHD) levels. To our knowledge, a study on 25OHD in children and adolescents with Prader-Willi syndrome (PWS), a genetic form of obesity, is not yet available. OBJECTIVE: To analyze the 25OHD values in pediatric PWS subjects in comparison with a control group (CNT), highlighting the possible correlations with IR, BMD, body composition, pubertal stage, and GH therapy (GHT). METHODS: Auxological and laboratory parameters, HOMA-IR, Vitamin D status, and bone density and body composition by DEXA scan were analyzed in 52 PWS and 110 controls (CNT), gender-, age-, and BMI-SD matched. None of them was on calcium or vitamin D. 20 PWS were on growth hormone (GH) therapy and 32 were previously treated. RESULTS AND CONCLUSION: Altogether, PWS had similar values of 25OHD compared to CNT.16 PWS (30.7%) and 27 CNT (24.5%) had low 25OHD levels (< 20 ng/ml) (p = NS). 25OHD of PWS on GHT were comparable to those previously treated. In both groups, univariate analysis showed a negative correlation between 25OHD and fat mass% (FM%). GH therapy and pubertal stage were positively correlated with bone parameters analyzed by DXA. Multivariate regression confirmed only FM% as negative predictor of 25HOD in PWS patients, as previously described. GHT does not seem to influence 25OHD in PWS. CONCLUSION: Our data showed that PWS had similar values of 25OHD compared to CNT. As already described, FM seems to be the only parameter influencing 25OHD levels. Finally, GHT does not seem to influence 25OHD metabolism in PWS.
PURPOSE:Obesity, insulin resistance, and puberty seem to influence and been inversely associated with 25-hydroxy vitamin D (25OHD) levels. To our knowledge, a study on 25OHD in children and adolescents with Prader-Willi syndrome (PWS), a genetic form of obesity, is not yet available. OBJECTIVE: To analyze the 25OHD values in pediatric PWS subjects in comparison with a control group (CNT), highlighting the possible correlations with IR, BMD, body composition, pubertal stage, and GH therapy (GHT). METHODS: Auxological and laboratory parameters, HOMA-IR, Vitamin D status, and bone density and body composition by DEXA scan were analyzed in 52 PWS and 110 controls (CNT), gender-, age-, and BMI-SD matched. None of them was on calcium or vitamin D. 20 PWS were on growth hormone (GH) therapy and 32 were previously treated. RESULTS AND CONCLUSION: Altogether, PWS had similar values of 25OHD compared to CNT.16 PWS (30.7%) and 27 CNT (24.5%) had low 25OHD levels (< 20 ng/ml) (p = NS). 25OHD of PWS on GHT were comparable to those previously treated. In both groups, univariate analysis showed a negative correlation between 25OHD and fat mass% (FM%). GH therapy and pubertal stage were positively correlated with bone parameters analyzed by DXA. Multivariate regression confirmed only FM% as negative predictor of 25HOD in PWSpatients, as previously described. GHT does not seem to influence 25OHD in PWS. CONCLUSION: Our data showed that PWS had similar values of 25OHD compared to CNT. As already described, FM seems to be the only parameter influencing 25OHD levels. Finally, GHT does not seem to influence 25OHD metabolism in PWS.
Entities:
Keywords:
Obesity; Prader–Willi syndrome; Vitamin D
Authors: D Fintini; C Brufani; A Grossi; G Ubertini; R Fiori; L Pecorelli; A Calzolari; M Cappa Journal: J Endocrinol Invest Date: 2010-09-17 Impact factor: 4.256
Authors: Craig F Munns; Nick Shaw; Mairead Kiely; Bonny L Specker; Tom D Thacher; Keiichi Ozono; Toshimi Michigami; Dov Tiosano; M Zulf Mughal; Outi Mäkitie; Lorna Ramos-Abad; Leanne Ward; Linda A DiMeglio; Navoda Atapattu; Hamilton Cassinelli; Christian Braegger; John M Pettifor; Anju Seth; Hafsatu Wasagu Idris; Vijayalakshmi Bhatia; Junfen Fu; Gail Goldberg; Lars Sävendahl; Rajesh Khadgawat; Pawel Pludowski; Jane Maddock; Elina Hyppönen; Abiola Oduwole; Emma Frew; Magda Aguiar; Ted Tulchinsky; Gary Butler; Wolfgang Högler Journal: J Clin Endocrinol Metab Date: 2016-01-08 Impact factor: 5.958
Authors: D Fintini; G Grugni; S Bocchini; C Brufani; S Di Candia; A Corrias; M Delvecchio; A Salvatoni; L Ragusa; N Greggio; A Franzese; E Scarano; G Trifirò; L Mazzanti; G Chiumello; M Cappa; A Crinò Journal: Nutr Metab Cardiovasc Dis Date: 2016-06-03 Impact factor: 4.222
Authors: Gillian E Walker; Roberta Ricotti; Marta Roccio; Stefania Moia; Simonetta Bellone; Flavia Prodam; Gianni Bona Journal: PLoS One Date: 2014-01-03 Impact factor: 3.240